The Effect of Zoledronic Acid on the Prevention of Bone Loss in Lymphoma Patients Receiving First-line Therapy
Clinical Lymphoma and Myeloma · 2009-12 · 9 (6) · E30
DOI: 10.3816/clm.2009.n.092 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma and Myeloma, 2009-12. Verfasst von Jason Westin und 17 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Westin, J., Hagemeister, F., Thompson, M. A., Cataldo, V. D., Toth, B. B., Sanjorjo, P., Bourgeois, S., Jimenez, C., Murphy, W. A., Fanale, M., Fayad, L., Fowler, N., Kwak, L., McLaughlin, P., Neelapu, S., Pro, B., Rodriguez, A., & Shah, J. (2009). The Effect of Zoledronic Acid on the Prevention of Bone Loss in Lymphoma Patients Receiving First-line Therapy. Clinical Lymphoma and Myeloma, 9(6), E30. https://doi.org/10.3816/clm.2009.n.092
Vancouver
Westin J, Hagemeister F, Thompson MA, Cataldo VD, Toth BB, Sanjorjo P, et al. The Effect of Zoledronic Acid on the Prevention of Bone Loss in Lymphoma Patients Receiving First-line Therapy. Clinical Lymphoma and Myeloma. 2009;9(6):E30. doi:10.3816/clm.2009.n.092
BibTeX
@article{Westin2009,
author = {Westin, Jason and Hagemeister, Fredrick and Thompson, Michael A. and Cataldo, Vince D. and Toth, Bela B. and Sanjorjo, Perpetua and Bourgeois, Scott and Jimenez, Camilo and Murphy, William A. and Fanale, Michelle and Fayad, Luis and Fowler, Nathan and Kwak, Larry and McLaughlin, Peter and Neelapu, Sattva and Pro, Barbara and Rodriguez, Alma and Shah, Jatin},
title = {The Effect of Zoledronic Acid on the Prevention of Bone Loss in Lymphoma Patients Receiving First-line Therapy},
journal = {Clinical Lymphoma and Myeloma},
year = {2009},
volume = {9},
number = {6},
pages = {E30},
doi = {10.3816/clm.2009.n.092}
}
EUVIMED